Maharashtra FDA Orders Recall Of Cadila Drugs Over Similar Brand Names
The Maharashtra Food and Drug Administration has stopped the sale and distribution of certain medicines manufactured by Cadila Pharmaceuticals and seized stocks worth about Rs 2.45 crore across the state over concerns that similar brand names could cause medication errors.The action covers Aciloc 150, Aciloc 150 Plus, Aciloc 300 and Aciloc 300 Plus. The regulator has directed the company to recall all available stocks of the four products and has specifically barred the sale of Aciloc 150 Plus and Aciloc 300 Plus.
Similar Branding Raises Medication Error Risk
The medicines contain ranitidine and famotidine, two chemically distinct active pharmaceutical ingredients used to treat acid reflux and related gastric conditions. Although both belong to the H2 receptor blocker category, they have different formulations and dosage requirements.
The FDA said near-identical brand names for medicines containing different ingredients could confuse doctors, pharmacists and patients, increasing the possibility of the wrong drug being prescribed, dispensed or consumed. Similar packaging may further raise the risk of mix-ups at pharmacies and among consumers.
FDA Commissioner Tukaram Mundhe said compliance with rules governing the branding, labelling and marketing of medicines was necessary to protect public health and patient safety.
The regulator has asked Cadila Pharmaceuticals to immediately withdraw existing stocks from the market. Further action will depend on the company’s response to the recall order and the outcome of the FDA’s continuing examination of the products.
The action is part of the Maharashtra FDA’s surveillance of pharmaceutical products sold in the state. The regulator routinely inspects manufacturing facilities, distribution networks and retail outlets to identify labelling violations, substandard medicines and other regulatory lapses.
The case highlights the potential safety risks associated with using similar brand names for medicines containing different active ingredients, even when the products are intended to treat related medical conditions.
Pages:
[1]